Skip Nav Destination
Issues
Featured Articles
Clinical Trials
Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer: A Pharmacokinetic and Long-Term Safety Study1
Laurens V. Beerepoot; Els O. Witteveen; Gerard Groenewegen; William E. Fogler; B. Kim Leel Sim; Carolyn Sidor; Bernard A. Zonnenberg; Franz Schramel; Martijn F. B. G. Gebbink; Emile E. Voest
Molecular Oncology, Markers, Clinical Correlates
Experimental Therapeutics, Preclinical Pharmacology
Regular Articles
Clinical Trials
A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors1
Sanjay Goel; Kavita Desai; Anca Bulgaru; Abbie Fields; Gary Goldberg; Sudhir Agrawal; Russell Martin; Michael Grindel; Sridhar Mani
Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
Hans Gelderblom; Ramon Salazar; Jaap Verweij; George Pentheroudakis; Maja J. A. de Jonge; Martin Devlin; Christel van Hooije; Francis Seguy; Rosendo Obach; Joan Pruñonosa; Paola Principe; Chris Twelves
A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer1
Roy S. Herbst; Lisa A. Hammond; David P. Carbone; Hai T. Tran; Kenneth J. Holroyd; Avinash Desai; Jon I. Williams; B. Nebiyou Bekele; Howard Hait; Victoria Allgood; Stephen Solomon; Joan H. Schiller
Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels: Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil1
Marko Kornmann; Wolfgang Schwabe; Silvia Sander; Martina Kron; Jörn Sträter; Sucan Polat; Erika Kettner; Hans F. Weiser; Wolfram Baumann; Harald Schramm; Peter Häusler; Kati Ott; Detlev Behnke; Ludger Staib; Hans G. Beger; Karl H. Link
Cancer Biology, Immunology Cytokines
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Consequences of Loss of Progesterone Receptor Expression in Development of Invasive Endometrial Cancer1
Eline E. Hanekamp; Susanne C. J. P. Gielen; Ellen Smid-Koopman; Liesbeth C. M. Kühne; Petra E. de Ruiter; Savi Chadha-Ajwani; Albert O. Brinkmann; J. Anton Grootegoed; Curt W. Burger; Frans J. Huikeshoven; Leen J. Blok
Experimental Therapeutics, Preclinical Pharmacology
Responsiveness to the Retinoic Acid Receptor-selective Retinoid LGD1550 Correlates with Abrogation of Transforming Growth Factor α/Epidermal Growth Factor Receptor Autocrine Signaling in Head and Neck Squamous Carcinoma Cells1
Miriam Lango; Abbey L. Wentzel; John I. Song; Sichuan Xi; Daniel E. Johnson; William W. Lamph; Lori Miller; Jennifer Rubin Grandis
Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET1
Wen G. Jiang; David Grimshaw; Tracey A. Martin; Gaynor Davies; Christian Parr; Gareth Watkins; Jane Lane; Roger Abounader; John Laterra; Robert E. Mansel
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.